ID

31640

Descripción

A Study of the Safety and Efficacy of Single-agent Carlumab (an Anti-Chemokine Ligand 2 [CCL2]) in Participants With Metastatic Castrate-Resistant Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00992186

Link

https://clinicaltrials.gov/show/NCT00992186

Palabras clave

Versiones (1)
  1. 15/9/18 15/9/18 -
Titular de derechos de autor

See clinicaltrials.gov

Subido en

15 de septiembre de 2018

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Prostate Cancer NCT00992186

Inglés

Eligibility Prostate Cancer NCT00992186

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
histological documentation of adenocarcinoma of the prostate
Descripción

Adenocarcinoma of prostate

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0007112
received at least 1 but no more than 2 prior docetaxel-based chemotherapy regimens and had disease progression following the last therapy
Descripción

Docetaxel Prior Chemotherapy Quantity | Disease Progression Post Therapeutic procedure

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0246415
UMLS CUI [1,2]
C1514457
UMLS CUI [1,3]
C1265611
UMLS CUI [2,1]
C0242656
UMLS CUI [2,2]
C0687676
UMLS CUI [2,3]
C0087111
serum prostate specific antigen (psa) greater than or equal to 5.0 nanogram/milliliter (ng/ml) within 4 weeks prior to the first dose of study agent
Descripción

Prostate specific antigen measurement

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0201544
orchiectomy (surgery to remove one or both testicles) or testosterone less than 50 nanogram/deciliter by means of pharmacological/chemical castration within 4 weeks prior to the first dose of study agent
Descripción

Orchiectomy | Testosterone measurement | Medical Castration | Chemical male castration

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0029189
UMLS CUI [2]
C0523912
UMLS CUI [3]
C1513054
UMLS CUI [4]
C0455189
at least 6 weeks from prior docetaxel chemotherapy regimen to first dose of study agent
Descripción

Docetaxel Prior Chemotherapy

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0246415
UMLS CUI [1,2]
C1514457
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
experience a hormonal treatment withdrawal response (including a lowering of psa that was previously rising or symptomatic improvement)
Descripción

Hormone Therapy Withdrawal Response | Prostatic specific antigen decreased | Raised prostate specific antigen Previous | Improvement Symptomatic

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0279025
UMLS CUI [1,2]
C2349954
UMLS CUI [1,3]
C1704632
UMLS CUI [2]
C0178414
UMLS CUI [3,1]
C0178415
UMLS CUI [3,2]
C0205156
UMLS CUI [4,1]
C2986411
UMLS CUI [4,2]
C0231220
known or symptomatic central nervous system metastases
Descripción

CNS metastases | CNS metastases Symptomatic

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0686377
UMLS CUI [2,1]
C0686377
UMLS CUI [2,2]
C0231220
residual toxicities resulting from previous therapy that are grade 2 or more (except for alopecia)
Descripción

Toxicity Due to Prior Therapy CTCAE Grades | Exception Relationship Alopecia

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0600688
UMLS CUI [1,2]
C0678226
UMLS CUI [1,3]
C1514463
UMLS CUI [1,4]
C1516728
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0439849
UMLS CUI [2,3]
C0002170
known allergies, hypersensitivity, or intolerance to carlumab or its excipients or clinically significant reactions to chimeric or human proteins
Descripción

Hypersensitivity Carlumab | Intolerance to Carlumab | Hypersensitivity Carlumab Excipient | Intolerance to Carlumab Excipient | Reaction Clinical Significance Fusion protein | Reaction Clinical Significance Proteins Human

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C2346793
UMLS CUI [2,1]
C1744706
UMLS CUI [2,2]
C2346793
UMLS CUI [3,1]
C0020517
UMLS CUI [3,2]
C2346793
UMLS CUI [3,3]
C0015237
UMLS CUI [4,1]
C1744706
UMLS CUI [4,2]
C2346793
UMLS CUI [4,3]
C0015237
UMLS CUI [5,1]
C0443286
UMLS CUI [5,2]
C2826293
UMLS CUI [5,3]
C0162768
UMLS CUI [6,1]
C0443286
UMLS CUI [6,2]
C2826293
UMLS CUI [6,3]
C0033684
UMLS CUI [6,4]
C0086418
vaccinated with live, attenuated vaccines within 4 weeks prior to the first dose of study agent
Descripción

Vaccines, Attenuated

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0042211
Volver a la parte superior de la página

Similar models

Eligibility Prostate Cancer NCT00992186

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Adenocarcinoma of prostate
Item
histological documentation of adenocarcinoma of the prostate
boolean
C0007112 (UMLS CUI [1])
Docetaxel Prior Chemotherapy Quantity | Disease Progression Post Therapeutic procedure
Item
received at least 1 but no more than 2 prior docetaxel-based chemotherapy regimens and had disease progression following the last therapy
boolean
C0246415 (UMLS CUI [1,1])
C1514457 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
C0242656 (UMLS CUI [2,1])
C0687676 (UMLS CUI [2,2])
C0087111 (UMLS CUI [2,3])
Prostate specific antigen measurement
Item
serum prostate specific antigen (psa) greater than or equal to 5.0 nanogram/milliliter (ng/ml) within 4 weeks prior to the first dose of study agent
boolean
C0201544 (UMLS CUI [1])
Orchiectomy | Testosterone measurement | Medical Castration | Chemical male castration
Item
orchiectomy (surgery to remove one or both testicles) or testosterone less than 50 nanogram/deciliter by means of pharmacological/chemical castration within 4 weeks prior to the first dose of study agent
boolean
C0029189 (UMLS CUI [1])
C0523912 (UMLS CUI [2])
C1513054 (UMLS CUI [3])
C0455189 (UMLS CUI [4])
Docetaxel Prior Chemotherapy
Item
at least 6 weeks from prior docetaxel chemotherapy regimen to first dose of study agent
boolean
C0246415 (UMLS CUI [1,1])
C1514457 (UMLS CUI [1,2])
Item Group
C0680251 (UMLS CUI)
Hormone Therapy Withdrawal Response | Prostatic specific antigen decreased | Raised prostate specific antigen Previous | Improvement Symptomatic
Item
experience a hormonal treatment withdrawal response (including a lowering of psa that was previously rising or symptomatic improvement)
boolean
C0279025 (UMLS CUI [1,1])
C2349954 (UMLS CUI [1,2])
C1704632 (UMLS CUI [1,3])
C0178414 (UMLS CUI [2])
C0178415 (UMLS CUI [3,1])
C0205156 (UMLS CUI [3,2])
C2986411 (UMLS CUI [4,1])
C0231220 (UMLS CUI [4,2])
CNS metastases | CNS metastases Symptomatic
Item
known or symptomatic central nervous system metastases
boolean
C0686377 (UMLS CUI [1])
C0686377 (UMLS CUI [2,1])
C0231220 (UMLS CUI [2,2])
Toxicity Due to Prior Therapy CTCAE Grades | Exception Relationship Alopecia
Item
residual toxicities resulting from previous therapy that are grade 2 or more (except for alopecia)
boolean
C0600688 (UMLS CUI [1,1])
C0678226 (UMLS CUI [1,2])
C1514463 (UMLS CUI [1,3])
C1516728 (UMLS CUI [1,4])
C1705847 (UMLS CUI [2,1])
C0439849 (UMLS CUI [2,2])
C0002170 (UMLS CUI [2,3])
Hypersensitivity Carlumab | Intolerance to Carlumab | Hypersensitivity Carlumab Excipient | Intolerance to Carlumab Excipient | Reaction Clinical Significance Fusion protein | Reaction Clinical Significance Proteins Human
Item
known allergies, hypersensitivity, or intolerance to carlumab or its excipients or clinically significant reactions to chimeric or human proteins
boolean
C0020517 (UMLS CUI [1,1])
C2346793 (UMLS CUI [1,2])
C1744706 (UMLS CUI [2,1])
C2346793 (UMLS CUI [2,2])
C0020517 (UMLS CUI [3,1])
C2346793 (UMLS CUI [3,2])
C0015237 (UMLS CUI [3,3])
C1744706 (UMLS CUI [4,1])
C2346793 (UMLS CUI [4,2])
C0015237 (UMLS CUI [4,3])
C0443286 (UMLS CUI [5,1])
C2826293 (UMLS CUI [5,2])
C0162768 (UMLS CUI [5,3])
C0443286 (UMLS CUI [6,1])
C2826293 (UMLS CUI [6,2])
C0033684 (UMLS CUI [6,3])
C0086418 (UMLS CUI [6,4])
Vaccines, Attenuated
Item
vaccinated with live, attenuated vaccines within 4 weeks prior to the first dose of study agent
boolean
C0042211 (UMLS CUI [1])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial